Drug intelligence / Profile preview

foslevcromakalim

Development stage: Phase 2
Lead developer: Qlaris Bio
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

QLS-101 is a novel prodrug of levcromakalim, an adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator. It works by lowering episcleral venous pressure (EVP) and increasing aqueous humor outflow through vessels distal to the trabecular meshwork, which reduces intraocular pressure (IOP). This unique mechanism of action differentiates it from other glaucoma treatments, as it specifically targets EVP, a key determinant of IOP. Developed by Qlaris Bio, it is administered as a topical eyedrop for the treatment of glaucoma and ocular hypertension.

Targets

SUR2B (Sulfonylurea receptor 2B)

Beyond the preview

Go deeper on foslevcromakalim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on foslevcromakalim.

Explore the full profile